Exosens Shares Drop 2.46% Ahead of Highly Anticipated Results
Exosens stock fell by 2.46% this Friday, trading at 63.50 euros compared to 65.10 euros the previous day. This decline occurs in a context of a generalized retreat in the defense and aerospace sector in Europe, as the publication of the first quarter 2026 results is expected on April 27.
The selling pressure observed this morning on Exosens is part of a sector-wide movement. Safran is down 3.05% and Airbus drops 2.78% during the session, while the CAC 40 is down 1.05% at 8,141 points. Across the Atlantic, major defense groups also finished in the red: Lockheed Martin lost 4.62% and RTX Corporation 0.89% at the day's close. Over the past week, Exosens shares have shown a decline of 3.79%, after a quarter still up by 15.88%. Over one year, the increase reaches 86.76%, reflecting the rapid valuation trajectory of the optoelectronic components specialist since its IPO. The upcoming quarterly results publication will be a test for the stock. Investors will then have concrete elements to assess the commercial dynamics of the group, particularly in its activities related to night vision and detection, at the heart of European defense programs. The general assembly scheduled for May 22 will be another closely watched event.
Technical Analysis of Exosens Stock
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Technically, Exosens stock is currently trading within its Bollinger bands, between the lower bound at 57.87 euros and the upper bound at 69.42 euros, indicating neither overbuying nor overselling. The 50-day moving average, located at 63.37 euros, almost acts as a center of gravity for the stock, which has been oscillating around this threshold for several sessions. The RSI at 53 confirms this neutrality, showing no significant divergence at this stage. The most closely watched support is at 57.50 euros: breaking below this level could alter the short-term outlook for the stock. Conversely, the identified resistance at 72.90 euros remains more than 14% above the current price. It should be noted that the negative beta of -0.66 indicates a historically decoupled behavior from the stock indices, a characteristic of some defense sector stocks whose activity depends more on government orders than on macroeconomic conditions.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.